Leerink Partners
Signal active
Investment Firm
Overview
Leerink Partners is a leading investment bank, specializing in healthcare. Their knowledge, experience and focus enable us to help their clients define and achieve their strategic, capital markets and investment objectives. They partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare.
Highlights
Founded
1995
Industry
Banking
Employees
251-500
Investment
17
Lead Investment
1
Exits
13
Stages
Early Stage Venture, Late Stage Venture
Investor Type
Investment Bank
Location
United States, North America
Contact Information
Social
Profile Resume
Leerink Partners, established in 1995 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across SaaS, Life Science, Analytics, Health Care, Financial Services, Venture Capital, Finance, Asset Management, Impact Investing, Media and Entertainment. The organization boasts a portfolio of 17 investments, with an average round size of $71.7M and 13 successful exits. Their recent investments include Humedica, General Catalyst, Bain Capital Ventures, North Bridge Venture Partners & Growth Equity, TESARO. The highest investment round they participated in was $193.7B. Among their most notable exits are Humedica and General Catalyst. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Leerink Partners has made 17 investments. Their most recent investment was on Dec 05, 2023, when Odyssey Therapeutics raised $101.0M.
Leerink Partners has made 10 diversity investments. Their most recent diversity investment was on Sep 05, 2018, when Fulcrum Therapeutics raised $80.0M.
investments
17
Diversity investments
10
Lead investments
1
Number of exits
13
Investments
17
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Sep 05, 2018 | Fulcrum Therapeutics | Biotechnology | 80.0M |
| May 23, 2019 | - | - | 120.0M |
| Aug 26, 2020 | Kinnate Biopharma | Biotechnology | 98.0M |
| Dec 05, 2023 | Odyssey Therapeutics | Biotechnology | 101.0M |
Exits
13
Funding Timeline
Funding rounds
17
Investors
1
Funds
2
Funding Rounds
17
Leerink Partners has raised 17 rounds. Their latest funding was raised on Dec 05, 2023 from a Series C - Odyssey Therapeutics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Sep 05, 2018 | Series B - Fulcrum Therapeutics | - | 80.0M | - |
| May 23, 2019 | Series B - AlloVir | - | 120.0M | - |
| Aug 26, 2020 | Series C - Kinnate Biopharma | - | 98.0M | - |
| Dec 05, 2023 | Series C - Odyssey Therapeutics | - | 101.0M | - |
Investors
1
Leerink Partners is funded by 1 investor(s). Lovell Minnick Partners Kantor is the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Lovell Minnick Partners | Yes | Private Equity Round - Leerink Partners | 0 |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.